FDA clears Roche’s bispecific Eylea contender, but can it compete with the Regeneron blockbuster?
The FDA finally approved Roche-Genentech’s Eylea rival late Friday, although precisely how much the long-acting antibody can cut into Regeneron’s blockbuster sales remains unclear.
The new drug, known chemically as faricimab and now marketed as Vabysmo, was OK’d for use in diabetic macular edema and wet age-related macular degeneration, one of the leading causes of blindness in older Americans. Regeneron has dominated the dual markets for nearly a decade with Eylea, an protein injected once every 8 or 12 weeks.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
